Francesca Aroldi

526 total citations
36 papers, 262 citations indexed

About

Francesca Aroldi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Francesca Aroldi has authored 36 papers receiving a total of 262 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 6 papers in Genetics. Recurrent topics in Francesca Aroldi's work include Colorectal Cancer Treatments and Studies (8 papers), Cancer Treatment and Pharmacology (6 papers) and Pancreatic and Hepatic Oncology Research (6 papers). Francesca Aroldi is often cited by papers focused on Colorectal Cancer Treatments and Studies (8 papers), Cancer Treatment and Pharmacology (6 papers) and Pancreatic and Hepatic Oncology Research (6 papers). Francesca Aroldi collaborates with scholars based in Italy, United Kingdom and United States. Francesca Aroldi's co-authors include Alberto Zaniboni, Paola Bertocchi, Mark R. Middleton, Tiziana Prochilo, Edoardo Rosso, Simon Lord, Fausto Meriggi, Giordano Savelli, Chiara Abeni and Anna Rizzi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cochrane Database of Systematic Reviews.

In The Last Decade

Francesca Aroldi

34 papers receiving 259 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Francesca Aroldi Italy 10 186 66 53 45 42 36 262
Teresa Smit South Africa 10 141 0.8× 31 0.5× 68 1.3× 96 2.1× 33 0.8× 38 304
Kenneth Friedman United States 8 145 0.8× 41 0.6× 57 1.1× 30 0.7× 19 0.5× 14 286
Luca Arecco Italy 15 280 1.5× 68 1.0× 84 1.6× 61 1.4× 38 0.9× 48 516
Jahan J. Mohiuddin United States 9 118 0.6× 94 1.4× 84 1.6× 17 0.4× 15 0.4× 21 268
Takeshi Uenami Japan 11 239 1.3× 231 3.5× 59 1.1× 37 0.8× 84 2.0× 33 407
Joel Gingerich Canada 8 154 0.8× 72 1.1× 119 2.2× 21 0.5× 45 1.1× 11 316
Vanesa de Luque Spain 3 255 1.4× 38 0.6× 69 1.3× 158 3.5× 17 0.4× 3 336
Eve‐Marie Neidhardt France 9 104 0.6× 71 1.1× 83 1.6× 23 0.5× 20 0.5× 28 249
Soo Young Hwang United States 9 52 0.3× 44 0.7× 101 1.9× 63 1.4× 48 1.1× 31 298
Sylvia ter Meulen Netherlands 7 162 0.9× 37 0.6× 58 1.1× 57 1.3× 44 1.0× 12 252

Countries citing papers authored by Francesca Aroldi

Since Specialization
Citations

This map shows the geographic impact of Francesca Aroldi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francesca Aroldi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francesca Aroldi more than expected).

Fields of papers citing papers by Francesca Aroldi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francesca Aroldi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francesca Aroldi. The network helps show where Francesca Aroldi may publish in the future.

Co-authorship network of co-authors of Francesca Aroldi

This figure shows the co-authorship network connecting the top 25 collaborators of Francesca Aroldi. A scholar is included among the top collaborators of Francesca Aroldi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francesca Aroldi. Francesca Aroldi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Spiliopoulou, Pavlina, Farasat Kazmi, Francesca Aroldi, et al.. (2024). A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301). Journal of Experimental & Clinical Cancer Research. 43(1). 100–100.
2.
3.
Aroldi, Francesca & Mark R. Middleton. (2022). Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma. American Journal of Clinical Dermatology. 23(3). 331–338. 23 indexed citations
4.
Aroldi, Francesca, et al.. (2022). Lag3: From Bench to Bedside. Cancer treatment and research. 183. 185–199. 9 indexed citations
5.
Aroldi, Francesca, et al.. (2020). 600TiP A first-in-human study of, NUC-7738, a 3'-dA phosphoramidate, in patients with advanced solid tumours (NuTide:701). Annals of Oncology. 31. S501–S501. 1 indexed citations
6.
Middleton, Mark R., Francesca Aroldi, Joseph J. Sacco, et al.. (2020). An open-label, single-arm, phase II clinical trial of RP1, an enhanced potency oncolytic herpes virus, combined with nivolumab in four solid tumor types: Initial results from the skin cancer cohorts.. Journal of Clinical Oncology. 38(15_suppl). e22050–e22050. 16 indexed citations
7.
Graham, Janet, Kristen K. Ciombor, Francesca Aroldi, et al.. (2020). 464P Pharmacokinetic analysis of NUC-3373 with and without leucovorin in patients with previously treated metastatic colorectal cancer (NuTide:302 study). Annals of Oncology. 31. S438–S439. 1 indexed citations
8.
Middleton, Mark R., Joseph J. Sacco, Jaime R. Merchan, et al.. (2019). Initial results of the phase 1 portion of an ongoing phase 1/2 study of RP1 as a single agent and in combination with nivolumab in patients with solid tumors. Journal for ImmunoTherapy of Cancer. 7. 1 indexed citations
9.
Prochilo, Tiziana, et al.. (2017). Hair loss prevention by scalp cooling device in early breast cancer patients: the Poliambulanza experience. Annals of Oncology. 28. vi35–vi35. 1 indexed citations
10.
Meriggi, Fausto, Chiara Abeni, Paola Bertocchi, et al.. (2017). Dignity Therapy: a new psychoterapeutic approach for people facing advanced disease. Annals of Oncology. 28. vi86–vi86. 1 indexed citations
11.
Aroldi, Francesca, Paola Bertocchi, Giordano Savelli, Edoardo Rosso, & Alberto Zaniboni. (2016). Pancreatic cancer: New hopes after first line treatment. World Journal of Gastrointestinal Oncology. 8(9). 682–682. 19 indexed citations
12.
Aroldi, Francesca, et al.. (2016). QT Prolongation and Anticancer Drugs: Is it a Cardiologist’s Worry? The Oncologist’s Point of View. Reviews on Recent Clinical Trials. 11(3). 260–265. 1 indexed citations
13.
Zimmitti, Giuseppe, Alberto Manzoni, Marco Ramera, et al.. (2016). Current Role of Minimally Invasive Radical Cholecystectomy for Gallbladder Cancer. Gastroenterology Research and Practice. 2016. 1–8. 14 indexed citations
14.
Meriggi, Fausto, Claudio Codignola, Anna Rizzi, et al.. (2016). Parents with cancer: Searching for the right balance between telling the truth and protecting children. Palliative & Supportive Care. 15(1). 88–97. 8 indexed citations
15.
Rizzi, Anna, Francesca Aroldi, Paola Bertocchi, et al.. (2016). GEMOX: An Active Regimen for the Treatment of Luminal and Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. Chemotherapy. 62(1). 30–33. 3 indexed citations
16.
Aroldi, Francesca, Paola Bertocchi, Edoardo Rosso, Tiziana Prochilo, & Alberto Zaniboni. (2015). Pancreatic Cancer: Promises and Failures of Target Therapies. Reviews on Recent Clinical Trials. 11(1). 33–38. 7 indexed citations
17.
Bertocchi, Paola, Chiara Abeni, Fausto Meriggi, et al.. (2015). Gemcitabine Plus Nab-Paclitaxel as Second-Line and Beyond Treatment for Metastatic Pancreatic Cancer: a Single Institution Retrospective Analysis. Reviews on Recent Clinical Trials. 10(2). 142–145. 19 indexed citations
18.
Aroldi, Francesca & Alberto Zaniboni. (2015). L’efficacia e la sicurezza dei farmaci antivascolari dopo gli anti-EGFR: aflibercept dopo cetuximab in un caso clinico. Recenti Progressi in Medicina. 106(12). 653e–6e.
19.
Prochilo, Tiziana, Francesca Aroldi, Paola Bertocchi, et al.. (2014). Blind Snipers: Relevant Off Target Effects of Non-chemotherapeutic Agents in Oncology: Review of the Literature. Reviews on Recent Clinical Trials. 9(2). 102–114. 3 indexed citations
20.
Aroldi, Francesca, Paola Bertocchi, Fausto Meriggi, et al.. (2014). Tyrosine Kinase Inhibitors in EGFR-Mutated Large-Cell Neuroendocrine Carcinoma of the Lung A Case Report. Case Reports in Oncology. 7(2). 478–483. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Teresa Smit Breakdown of academic impact, for papers by Kenneth Friedman Breakdown of academic impact, for papers by Luca Arecco Breakdown of academic impact, for papers by Jahan J. Mohiuddin Breakdown of academic impact, for papers by Takeshi Uenami Breakdown of academic impact, for papers by Joel Gingerich Breakdown of academic impact, for papers by Vanesa de Luque Breakdown of academic impact, for papers by Eve‐Marie Neidhardt Breakdown of academic impact, for papers by Soo Young Hwang Breakdown of academic impact, for papers by Sylvia ter Meulen
Rankless by CCL
2026